While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. That said, here is one profitable company that leverages its financial strength to beat the competition and two that may face some trouble.
Two Stocks to Sell:
NXP Semiconductors (NXPI)
Trailing 12-Month GAAP Operating Margin: 32%
Spun off from Dutch electronics giant Philips in 2006, NXP Semiconductors (NASDAQ: NXPI) is a designer and manufacturer of chips used in autos, industrial manufacturing, mobile devices, and communications infrastructure.
Why Do We Think Twice About NXPI?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Estimated sales growth of 15.4% for the next 12 months is soft and implies weaker demand
NXP Semiconductors’s stock price of $237.28 implies a valuation ratio of 14.1x forward P/E. Read our free research report to see why you should think twice about including NXPI in your portfolio.
Titan International (TWI)
Trailing 12-Month GAAP Operating Margin: 1.4%
Acquiring Goodyear’s farm tire business in 2005, Titan (NYSE:TWI) is a manufacturer and supplier of wheels, tires, and undercarriages used in off-highway vehicles such as construction vehicles.
Why Are We Bearish on TWI?
- Muted 1.7% annual revenue growth over the last two years shows its demand lagged behind its industrials peers
- Diminishing returns on capital suggest its earlier profit pools are drying up
- 5× net-debt-to-EBITDA ratio shows it’s overleveraged and increases the probability of shareholder dilution if things turn unexpectedly
At $6.94 per share, Titan International trades at 8.5x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why TWI doesn’t pass our bar.
One Stock to Watch:
AbbVie (ABBV)
Trailing 12-Month GAAP Operating Margin: 26.2%
Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.
Why Do We Like ABBV?
- Unparalleled scale of $64.39 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
- ABBV is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
- Industry-leading 18.6% return on capital demonstrates management’s skill in finding high-return investments
AbbVie is trading at $263.20 per share, or 17.6x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.